Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin Receives FDA Approval for Generic Monodox® Capsules and Cipro® for Oral Suspension.
Lupin Receives FDA Approval for Generic Mycobutin® Capsules.
Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy.
Lupin Acquires Nanomi B.V. Enters Complex Injectables Space.
Strong Growth, Record Profits Quarter III Results, FY 2013-14 Net Sales up 21%, EBITDA up 28%, Net profit up 42% Declares Interim Dividend of 150%.
Lupin launches Generic Trizivir® Tablets.
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.
Created and Designed by